Captor Therapeutics repeated its goal. Captor Therapeutics stock costs EUR 15.22 versus EUR 15.30

Published on 10/08/2026 at 11:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Captor reported a PLN 22.76 million net loss in the first half of 2026. Captor Therapeutics stock costs EUR 15.22 on October 8, 2026 after EUR 15.30.

Captor Therapeutics, PLCPTRT00014, Illustration mit AI erstellt.

Captor Therapeutics stock (ISIN PLCPTRT00014) was trading at EUR 15.22 at Lang & Schwarz on October 8, 2026 at 11:17 a.m. CEST, with a minus 0.52 percent change versus the prior close of EUR 15.30. As Bankier.pl reported on September 18, 2026, management had repeated its goal of signing a partnering agreement in 2026.

Funding reaches the third quarter of 2027

Management said Captor had PLN 71.50 million in cash and investments at June 30, 2026, providing a funding runway through the third quarter of 2027. The same update said 13 patients had received treatment in four dose levels in the phase 1 CT-01 study.

The partnering goal is important because it links the cash position to a potential business-development milestone rather than to a near-term revenue expansion. Management also said the company planned to change its clinical research organization provider within two to three months.

First-half loss widens 11.17 percent

PB.pl published Captor's half-year report on September 15, 2026. Research and development service revenue fell to PLN 1.96 million in the first half of 2026 from PLN 4.62 million in the first half of 2025, a decline of 57.50 percent.

The reported net loss reached PLN 22.76 million in the first half of 2026, compared with PLN 20.47 million a year earlier, so the loss widened 11.17 percent. Operating cash flow was negative PLN 24.63 million for the period, while equity stood at PLN 65.07 million at June 30, 2026.

Stock stays below its prior close

The Lang & Schwarz quote stood at EUR 15.22 on October 8, 2026 at 11:17 a.m. CEST, versus the EUR 15.30 prior close, a minus 0.52 percent change. On the Warsaw Stock Exchange, the stock had a PLN 37.70 to PLN 89.20 52-week range and a market capitalization of PLN 419.9 million as of October 8, 2026.

The further course of trading is shown by the continuously updated real-time quote of Captor Therapeutics stock.